Please use this identifier to cite or link to this item:
|Title:||Insulin glargine and its role in glycaemic management of Type 2 diabetes.|
|Citation:||EXPERT OPIN DRUG METAB TOXICOL, 2008, 4 (8), pp. 1099-1110|
|Abstract:||Insulin glargine (Lantus) was the first recombinant-DNA long-acting insulin analogue to be licensed for use in the treatment of diabetes mellitus.|
|Appears in Collections:||Published Articles, Dept. of Cardiovascular Sciences|
Files in This Item:
There are no files associated with this item.
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.